ClinicalTrials.Veeva

Menu
Perceptive Pharma Research | Richmond, TX logo

Perceptive Pharma Research | Richmond, TX

Research site
About
Clinical trials

Site insights

Top conditions

Top treatments

Etrasimod
BI 425809
KarXT
TEV-48574
ABX464
Valbenazine
Ralmitaront
SLS-002
Elafibranor
Ecopipam Hydrochloride

Parent organization

This site is a part of Perceptive Pharma Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Research coordinator

Verified by this site

Active trials

22 of 43 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: Etrasimod

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Enrolling
Anhedonia
Depressive Disorder, Major
Drug: Aticaprant
Other: Placebo

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose fi...

Enrolling
Rheumatoid Arthritis
Drug: SAR441566
Drug: Placebo

The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered e...

Active, not recruiting
Colitis, Ulcerative
Crohn Disease
Drug: TEV-48574 Dose Regiment B
Drug: TEV-48574 Dose Regimen A

The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficac...

Enrolling
Colitis Ulcerative
Drug: Placebo
Drug: Dupilumab

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults...

Active, not recruiting
Tourette Disorder
Drug: Ecopipam Hydrochloride

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficac...

Enrolling
Ulcerative Colitis
Drug: SPH3127
Drug: Placebo

The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants...

Enrolling
Schizophrenia
Drug: Valbenazine
Drug: Placebo

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patie...

Enrolling
Major Depressive Disorder
Drug: ALTO-300
Drug: Placebo

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (...

Active, not recruiting
Primary Biliary Cholangitis
Drug: Obeticholic Acid placebo
Drug: Obeticholic Acid 5 mg

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how saf...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Placebo for ABBV-932
Drug: ABBV-932

Trial sponsors

AbbVie logo
Boehringer Ingelheim logo
A
Click Therapeutics logo
Janssen (J&J Innovative Medicine) logo
Karuna Therapeutics logo
Neurocrine Biosciences logo
Pfizer logo
Sanofi logo
Teva Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems